MARKET NEWS

 

Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol in Reversal of Mydriasis
Synlogic Presents Data Demonstrating Reductions in Plasma Phenylalanine Levels in Patients With Phenylketonuria Treated With SYNB1618
Owen Mumford Announces £14-Million Investment in New, State-of-the-Art BREEAM-Certified Premises
Zealand Pharma Announces Successful Outcome of Phase 1b Clinical Trial With GLP1-GLP2 Dual Receptor Agonist
Apollomics Doses First Patient in Phase 3 Clinical Trial With APL-106 (Uproleselan Injection) in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia
Stanford Scientists First to Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart

  FEATURED EDITORIAL

 

  COMPANY PROFILE

At Gattefossé, each excipient is designed to meet a unique set of formulation and functionality objectives while conforming to the highest safety, quality, and regulatory standards. Product applications include solubility and bioavailability enhancers; sustained/controlled release matrix formers; protective coatings or taste masking agents for actives; emulsifying bases for topical dosage forms; skin penetration and permeation enhancers; and carriers for suppository bases and vaginal pessaries. Among our renown products are Compritol, Labrafil, Gelucire, Labrasol, Capryol, Lauroglycol, Precirol, Tefose, and Suppocire series. Globally established for safety and pharmaceutical qualifications, many of these excipients are also found in pediatric dosage forms. Click here for more.

  EXCLUSIVE ONLINE CONTENT

 

Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Revive Therapeutics Ltd. recently announced it has filed an application with the US FDA to receive Orphan Drug Designation (ODD) for Bucillamine for the prevention of ischemia–reperfusion injury (IRI) during liver….

Diffusion Pharmaceuticals Doses First Participants in Altitude Trial

Diffusion Pharmaceuticals Doses First Participants in Altitude Trial

Diffusion Pharmaceuticals Inc. recently announced it has dosed the first participants in its Altitude Trial. The trial will evaluate the company’s lead product candidate, trans sodium crocetinate (TSC)….

Decibel Therapeutics Announces Extension of Research Term Under Strategic Collaboration With Regeneron to Discover & Develop Gene Therapies for Hearing Loss

Decibel Therapeutics Announces Extension of Research Term Under Strategic Collaboration With Regeneron to Discover & Develop Gene Therapies for Hearing Loss

Decibel Therapeutics recently announced that Regeneron has extended the research term of its collaboration with the company to discover and develop gene therapies for hearing loss…..

Cytovia & Cellectis Expand Their TALEN Gene-Edited iNK Partnership to Enable Broader Collaboration in China

Cytovia & Cellectis Expand Their TALEN Gene-Edited iNK Partnership to Enable Broader Collaboration in China

Cytovia Therapeutics, Inc. and Cellectis recently announced they have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells to include new CAR target and….

ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing & Manufacturing Next-Generation COVID-19 Vaccines

ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing & Manufacturing Next-Generation COVID-19 Vaccines

ImmunityBio, Inc. recently announced the expansion of the company’s cancer and infectious disease vaccine programs to include self-amplifying self-adjuvating RNA (SASA-RNA), recombinant protein vaccine candidates, and potent adjuvant formulations that….

Artizan Biosciences & Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease

Artizan Biosciences & Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease

Artizan Biosciences, Inc. and Biohaven Therapeutics Ltd. recently announced the companies are initiating a therapeutic discovery and development program in Parkinson’s disease (PD), to exploit recent….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

December 10 – Prefilled Syringes
December 17 – Injection Devices